Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2600-2603

  Lubasch, A ^a   Keller, I ^a   Borner, K ^a   Koeppe, P ^a   Lode, H ^a  

^a Chest Hospital Heckeshorn   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; TROVAFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HUMANS; MALE;

EID: 0033802359     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2600-2603.2000     Document Type: Article

References (18)

1. The quinolones: Prospects
2. Pharmacokinetics of the fluoroquinolones
3. Determination of trovafloxacin in human body fluids by high-performance liquid chromatography
4. Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids
5. Chromatographische Bestimmung yon Ofloxacin in Korperflussigkeiten
6. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration
7. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects
8. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
9. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin
10. Pharmacokinetics of grepafloxacin
11. Trovafloxacin
12. REVOLnon-linear regression based on strategy of evolution
13. New regression function for absorption kinetics
14. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminium and magnesium
15. Estimating the dimension of a model
16. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects
17. Oral bioavailability of trovafloxacin with and without food in healthy volunteers
18. Pharmacokinetics and inflammatory fluid penetration of moxifloxacin following oral or intravenous administration